AdipoPharma

company

We are developing PATAS, a unique first-in-class insulin sensitizer that targets the adipocyte and that will treat insulin resistance, type 2 diabetes and associated comorbidities.

Targeted Innovation

PATAS Peptide

Clinical Expertise

Metabolic Balance

What is AdipoPharma?

We are a French biotech company committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis.

The company was created to commercialize the work of its founder, Dr. Vincent Marion PhD, MSc, and Biochemist and researcher at INSERM, the French National Institute for Health and Medical Research. Dr Marion’s team has spent more than a decade identifying therapeutic targets based on the adipocyte’s specific role in the metabolic effects of insulin resistance and diabetes.

This work began by the detailed genetic investigation of Alström syndrome, an ultra-rare devastating disease characterized by severe insulin resistance, early-onset type 2 diabetes and associated metabolic dysfunctions.

This led to the development of a detailed analysis of the adipocyte’s complex function, its intrinsic lipid modulating effects and a proprietary targeted approach to treatment.

The result is AdipoPharma’s innovative and first-in-class therapeutic peptide “PATAS”, which enter clinical trial phase in 2025. This safe and novel therapeutic approach has been shown to restore healthy lipid biosynthesis in the diseased adipocyte leading to reduction of unhealthy lipids like the ceramides. PATAS is set to be the first anti-diabetic drug to have a significant beneficial effect on insulin resistance, beta cell plaque removal, liver steatosis and fibrosis and ceramides, the leading cause of cardiovascular dysfunction in diabetes.

Our Science

Inspired by genetic-derived knowledge to design innovative metabolic drugs targeting the adipocyte

Redefining Diabetes Treatment

AdipoPharma is pioneering a new class of metabolic therapy using stapled peptides designed to restore the natural function of adipocytes, the fat cells at the heart of metabolic regulation.

By specifically targeting insulin resistance, our lead therapeutic, PATAS, addresses the root cause of type 2 diabetes rather than just managing symptoms.

This innovative approach aims to reduce toxic lipids like ceramides, improve liver health, and support pancreatic β-cell function, offering new hope for millions affected by this chronic disease.